粪菌移植与肝癌

doi:10.3969/j.issn.1672-5069.2017.06.005

Abstract

Zhang Lei，Liu Chao. Fecal microbiota transplantation in primary liver cancer[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 658-659.

[1] Rooks MG，Garrett WS. Gut microbiota，metabolites and host immunity. Nat Rev Immunol，2016，16（6）:341-352.
[2] Schroeder BO，Backhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med，2016，22（10）:1079-1089.
[3] Schwabe RF，Jobin C. The microbiome and cancer. Nat Rev Cancer，2013，13（11）:800-812.
[4] Koeth RA，Wang Z，Levison BS，et al. Intestinal microbiota metabolism of L-carnitine，a nutrient in red meat，promotes atherosclerosis. Nat Med，2013，19（5）:576-585.
[5] Zhu W，Gregory JC，Org E，et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell， 2016，165（1）:111-124.
[6] Schnabl B，Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology，2014，146（6）:1513-1524.
[7] Tao X，Wang N，Qin W. Gut microbiota and hepatocellular carcinoma. Gastrointest Tumors，2015，2（1）:33-40.
[8] Dapito DH，Mencin A，Gwak GY，et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell，2012，21（4）:504-516.
[9] Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol，2009，9（11）:799-809.
[10] Peterson LW，Artis D. Intestinal epithelial cells:regulators of barrier function and immune homeostasis. Nat Rev Immunol，2014，14（3）:141-153.
[11] Jirillo E，Caccavo D，Magrone T，et al. The role of the liver in the response to LPS:experimental and clinical findings. J Endotoxin Res，2002，8（5）:319-327.
[12] Haque TR，Barritt ASt. Intestinal microbiota in liver disease. Best Pract Res Clin Gastroenterol，2016，30（1）:133-142.
[13] Wiest R，Albillos A，Trauner M，et al. Targeting the gut-liver axis in liver disease. J Hepatol，2017，[ahead of print].
[14] Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology，2015，148（1）:30-36.
[15] Mima K，Nakagawa S，Sawayama H，et al. The microbiome and hepatobiliary-pancreatic cancers. Cancer Lett，2017，402:9-15.
[16] El-Serag HB. Hepatocellular carcinoma. N Engl J Med，2011，365（12）:1118-1127.
[17] Fatima N，Akhtar T，Sheikh N. Prebiotics:A novel approach to treat hepatocellular carcinoma. 2017，2017:6238106.
[18] Seki E，De Minicis S，Osterreicher CH，et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med，2007，13（11）:1324-1332.
[19] Yu LX，Yan HX，Liu Q，et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology，2010，52（4）:1322-1333.
[20] O'Neill LA，Golenbock D，Bowie AG. The history of Toll-like receptors-redefining innate immunity. Nat Rev Immunol，2013，13（6）:453-460.
[21] Achiwa K，Ishigami M，Ishizu Y，et al. DSS colitis promotes tumorigenesis and fibrogenesis in a choline-deficient high-fat diet-induced NASH mouse model. Biochem Biophys Res Commun， 2016，470（1）:15-21.
[22] Yu LX，Schwabe RF. The gut microbiome and liver cancer:mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol，2017，[ahead of print].
[23] Qin N，Yang F，Li A，et al. Alterations of the human gut microbiome in liver cirrhosis. Nature，2014，513（7516）:59-64.
[24] Wei X，Jiang S，Chen Y，et al. Cirrhosis related functionality characteristic of the fecal microbiota as revealed by a metaproteomic approach. BMC Gastroenterol，2016，16（1）:121.
[25] Chen Y，Ji F，Guo J，et al. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Sci Rep，2016，6:34055.
[26] Bauer TM，Schwacha H，Steinbruckner B，et al. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol，2002，97（9）:2364-2370.
[27] Bajaj JS，Betrapally NS，Hylemon PB，et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology，2015，62（4）:1260-1271.
[28] Zhang HL，Yu LX，Yang W，et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol，2012，57（4）:803-812.
[29] Hara E. Relationship between obesity，gut microbiome and hepatocellular carcinoma development. Dig Dis，2015，33（3）:346-350.
[30] Yoshimoto S，Loo TM，Atarashi K，et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature，2013，499（7456）:97-101.
[31] Zhu Q，Zou L，Jagavelu K，et al. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol，2012，56（4）:893-899.
[32] Steib CJ，Hartmann AC，v Hesler C，et al. Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. Lab Invest，2010，90（7）:1024-1032.
[33] Lutz P，Parcina M，Bekeredjian-Ding I，et al. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. PLoS One，2014，9（4）:e93909.
[34] Bass NM，Mullen KD，Sanyal A，et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med，2010，362（12）:1071-1081.
[35] Smits LP，Bouter KE，de Vos WM，et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology，2013，145（5）:946-953.
[36] van Nood E，Vrieze A，Nieuwdorp M，et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med，2013，368（5）:407-415.
[37] Darnaud M，Faivre J，Moniaux N. Targeting gut flora to prevent progression of hepatocellular carcinoma. J Hepatol，2013，58（2）:385-387.
[38] Iida N，Dzutsev A，Stewart CA，et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science，2013，342（6161）:967-970.
[39] Vrieze A，Van Nood E，Holleman F，et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology，2012，143（4）:913-916.e917.
[40] Nanji AA，Khettry U，Sadrzadeh SM. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver （disease）. Proc Soc Exp Biol Med，1994，205（3）:243-247.
[41] Liu Q，Duan ZP，Ha DK，et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology，2004，39（5）:1441-1449.

Fecal microbiota transplantation in primary liver cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liu Xing, Zhao Shuli, Zhang Dianlong. Effect of sevoflurane inhalation on hepatic ischemia-reperfusion injury in patients with primary liver cancer undergoing partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(5): 728-731.
[2]	Pei Ying, Huang Feng, Yin Hongzhen, et al. Preliminary study on intestinal microecology in mice with xenograft hepatoma intervened by sodiumnorcantharidate [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 486-489.
[3]	Dai Qingyun, Wang Rundong, Jia Weidong. Prediction of early tumor recurrence by predictive nutritional index in patients with hepatocellular carcinoma undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 561-564.
[4]	Cui Faqiang, Li Tao, Wang Zheng, et al. A pilot study on cetuximab and KRAS gene mutation in treatment of patients with primary liver cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 565-568.
[5]	Yang Fucun, Shang Huaixue, Gai Yonghao. Enhanced magnetic resonance imaging by gadolinium disodium sebacate in diagnosis of patients with focal liver lesions [J]. Journal of Practical Hepatology, 2019, 22(4): 577-580.
[6]	Peng Xinjian, Xiao Yuhui, Xu Siding. Diagnostic value of diffusion-weighted magnetic resonance imaging in patients with radiation-induced liver injury with underlying hepatocelullar carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 373-376.
[7]	Zhao Xiaoguang, Shi Yujie. Protective effect of reduced glutathione on liver function in patients with advanced primary liver cancer underwent transarterial chemoembolization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 425-428.
[8]	Li Ketian, Shen Mingge, Wang Fengrong, Hu Chunrong, Cao Yujie, Lu Peng. Impact of blood glucose levels on imaging quality of PET/CT examination in patients with primary liver cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 256-259.
[9]	Zhang Bangjian, Wei Shoucun, Yang Xiaoyan. Effects of dexmedetomidine combined with propofol anesthesia on perioperative stress response and postoperative recovery quality in patients undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 264-267.
[10]	Xu Dafeng, Zhou Kailun, Li Zhuori, et al.. Preliminary observation of miR-144 liposomes on inhibition of proliferation, migration and invasion of liver cancer cells in vitro and in vivo [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 25-28.
[11]	Li Fang, Zou Guizhou, Gao Yufeng, et al.. Frequency of PD-1 copy number variation in individuals with hepatitis B viral infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 37-40.
[12]	Wang Cuixiao, Gao Jing.. Serum Golgi protein 73, lentil lectin-reactive alpha-fetoprotein-L3,AFP andα-L- fucosidase levels in patients with primary liver cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 113-116.
[13]	Dai Xiaonan, Lyu Jinyan, Weng Wencai, et al.. Expression of IFITM3 in hepatocellular carcinoma and its correlation with intrahepatic tumor recurence after hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 117-120.
[14]	Chen Xiang, Wang Baolin, Wu Chen, et al.. Efficacy of transcatheter arterial chemoembolization and radion implantation in the treatment of patients with primary liver cancer and its impact on hepatic expressions of TRF1 and TRF2 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 121-124.
[15]	Ma Lyuxiang, Zhang Xuesong.. Efficacy and prognosis of ultrasound-guided percutaneous radiofrequency ablation in treatment of patients with small hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 125-128.